Prostate cancer gene therapy - Corautus Genetics
Alternative Names: IL-3 Dual-ADLatest Information Update: 29 May 2003
At a glance
- Originator Corautus Genetics
- Developer Corautus Genetics; Immune Response Corporation
- Class Antineoplastics; Gene therapies
- Mechanism of Action Immunomodulators; Interleukin 3 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 29 May 2003 Discontinued - Preclinical for Prostate cancer in USA (Intratumoural)
- 19 Feb 2003 GenStar Therapeutics Corporation has merged with Vascular Genetics to form Corautus Genetics
- 17 Feb 2003 Suspended - Preclinical for Prostate cancer in USA (Intratumoural)